Associate Professor, Medicine, University of Texas Medical School, San Antonio
Endocrinology
Dr. Eugenio Cersosimo, MD
|
|
Give Review
Eugenio Cersosimo practices Endocrinology. Eugenio Cersosimo is also a published doctor. He has 67 paper published. The most recent paper is: Insulin regulation of renal glucose metabolism in humans. He is registered with Medicare.
Publications
- Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 Diabetes mellitus.
- The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
- Initial Combination Therapy with Metformin/Pioglitazone/Exenatide is More Effective Than Sequential Add-On Therapy in Subjects with New Onset Diabetes. Results from th...
- Inhibition of renal glucose reabsorption as a novel treatment for Diabetes patients.
- Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications.
- The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in Type ...
- Genetic epidemiology of cardiometabolic risk factors and their clustering patterns in Mexican American children and adolescents: the SAFARI Study.
- Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.
- To pump or not to pump?
- Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 Diabetes.
- Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated Type 2 diabetic patients.
- Coexistence of malignant struma ovarii and Graves' Disease.
- Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nonDiabetic subjects.
- Insulin resistance and endothelial dysfunction: the road map to cardiovascular Diseases.
- Comparison of glargine insulin versus rosiglitazone addition in poorly controlled Type 2 diabetic patients on metformin plus sulfonylurea.
- Comprehensive assessment of postischemic vascular reactivity in Hispanic children and adults with and without Diabetes mellitus.
- Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 Diabetes treated with pioglitazone.
- Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to Type 2 ...
- Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 Diabetes: a time-course and dose-response study.
- Addition of pioglitazone and ramipril to intensive insulin therapy in Type 2 diabetic patients improves vascular dysfunction by different mechanisms.
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 Diabetes.
- Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects.
- Chronic low-dose Lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.
- Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 Diabetes: a double tracer OGTT study.
- NF-?B activity in muscle from obese and Type 2 diabetic subjects under basal and exercise-stimulated conditions.
- Pioglitazone and alogliptin combination therapy in type 2 Diabetes: a pathophysiologically sound treatment.
- Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and Type 2 diabetic subjects.
- Improving treatment in Hispanic/Latino patients.
- Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways.
- Rosiglitazone decreases albuminuria in Type 2 diabetic patients.
- Effects of insulin and oral anti-diabetic agents on glucose Metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
- Effect of exenatide on splanchnic and peripheral glucose Metabolism in type 2 diabetic subjects.
- Metabolic effects of muraglitazar in Type 2 diabetic subjects.
- Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fa...
- Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II Diabetes mellitus.
- Parenteral nutrition in the management of acute Renal failure.
- Isolated antral narrowing associated With gastrointestinal cryptosporidiosis in acquired immunodeficiency syndrome.
- Insulin action on glucose and branched-chain amino acid Metabolism in cancer cachexia: differential effects of insulin.
- The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man.
- Insulin secretion and action in patients With pancreatic cancer.
- The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia.
- Glutamine Metabolism during starvation.
- Inter-organ Metabolism of amino acids in vivo.
- Physiologic importance of glutamine.
- Importance of ammonium ions in regulating hepatic glutamine synthesis during fasting.
- Glutamine blocks lipolysis and ketogenesis of fasting.
- Role of glutamine in adaptations in nitrogen Metabolism during fasting.
- alpha-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans.
- Role of acidosis in regulating hepatic nitrogen Metabolism during fasting in conscious dog.
- Interorgan relationships of alanine and glutamine during fasting in the conscious dog.
- Insulin regulation of renal glucose Metabolism in conscious dogs.
- Lack of effect of hyperglycemia on lipolysis in humans.
- "Suspicious" Thyroid cytologic findings: outcome in patients without immediate surgical treatment.
- Effects of pulsatile delivery of basal growth hormone on lipolysis in humans.
- Renal glucose production during insulin-induced hypoglycemia.
- Role of the kidney in plasma glucose regulation during hyperglycemia.
- Techniques for assessing protein and glucose kinetics.
- Renal lactate Metabolism and gluconeogenesis during insulin-induced hypoglycemia.
- Effects of beta-adrenergic blockade on hepatic and Renal glucose production during hypoglycemia in conscious dogs.
- Insulin regulation of renal glucose Metabolism in humans.
- Renal glucose production during insulin-induced hypoglycemia in humans.
- Application of high-performance liquid chromatography of plasma fatty acids as their phenacyl esters to evaluate splanchnic and Renal fatty acid balance in vivo.
- Regulation of splanchnic and Renal substrate supply by insulin in humans.
- Renal substrate Metabolism and gluconeogenesis during hypoglycemia in humans.
- Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes.
- Short-term exercise training improves insulin sensitivity but does not inhibit inflammatory pathways in immune cells from insulin-resistant subjects.
Schools
Universidade Federal Fluminense Centro De Ciencias Medicas
Mayo Clinic Rochester
Conditions Treated
- Abnormal Thyroid
- Adrenogenital Disorders
- Calcium Metabolism Disorders
- Diabetes Type 1
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Preferred PPO
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
Education
-
Mayo School of Graduate Medical Education
Hospital
-
University Health System
Drug Facts
| NPI NUMBER | 1396756409 | |
| NPPES Provider LastName | CERSOSIMO | |
| NPPES Provider FirstName | EUGENIO | |
| NPPES Provider ZIPCode | 782075209 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 383.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396756409 |
| Last Name Of The Provider | CERSOSIMO |
| First Name Of The Provider | EUGENIO |
| View All |
Similar Doctors
|
|
Dr. Mark W. True, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Reasner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Kohl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicolas Musi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|